12 December 2025
EMA/CVMP/AWP/289168/2025
Committee for Veterinary Medicinal Product (CVMP)

Work plan for the Committee for Veterinary Medicinal Products (CVMP) Antimicrobials Working Party (AWP) 2026

Chairpersons	Status
Chair: Damien Bouchard Vice-chair: Boudewijn Catry	Adopted by CVMP in December 2025

The activities outlined in the work plan for 2026 have been agreed considering the respective business priorities and may be subject to further review and reprioritisation in accordance with the business plan of the Agency.

1. Meetings scheduled for 2026

Plenary meetings: 4 (per meeting: 12 members, 2 days)

Virtual meeting	17-18 March 2026
Physical meeting	02-03 June 2026
Virtual meeting	22-23 September 2026
Virtual meeting	24-25 November 2026

Other meetings:

Drafting / Expert groups	4-6 (mostly virtual, 3-12 participants)
Workshop / Focus group	None
Trainings	None

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

2. Product related issues

The following table provides the expected number per year of contributions (number of involvements in dossier) for scientific advice and product assessment, including pre- and post-authorisation issues.

Expected contribution in Scientific Advice	Expected contribution in Product Assessment
2	4

3. CVMP guidance documents

3.1. Guidance documents to be finalised after the consultation period

3.1.1. Reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on human and animal health

Action: Finalisation of the reflection paper on macrolides, lincosamides and streptogramins.

Priority 2, Start date: ongoing, Completion date: Q3 2026

Comments: Responsible groups: AWP (consultation with ERAWP, IDWP and SWP-V). Concept paper (EMA/CVMP/AWP/266787/2021) published in October 2021.

3.2. Guidance documents to be released for consultation

3.2.1. Guideline on the assessment of the risk to public health from antimicrobial resistance due to antimicrobial use in non-food-producing animal species

Action: Work on the guideline to be initiated, following public consultation.

Priority 1, Start date: Q1 2026, Completion date: beyond 2026

Comments: Responsible groups: AWP (consultation with IDWP). Concept paper (EMA/CVMP/AWP/109142/2025) published in November 2025. Comments received on the 'Reflection paper on the risk of antimicrobial resistance transfer from companion animals' (EMA/CVMP/AWP/401740/2013) published in 2015 will also be considered during the preparation of this guideline.

3.2.2. Reflection paper on the assessment of public health risks related to antimicrobial resistance acquired via the environment, resulting from the use of a VMP

Action: Work on the reflection paper to be initiated, following public consultation.

Priority 2, Start date: Q1 2026, completion date: beyond 2026.

Comments: Responsible groups: ERAWP-V with AWP. Concept paper (EMA/CVMP/ERA/75412/2023) published in April 2025.

3.2.3. Reflection paper on the availability and characteristics of diagnostic tests to improve the responsible use of antibiotics in animals

Action:	Finalisation of the reflection paper on the availability and characteristics of diagnostic tests to improve the responsible use of antimicrobials in animals. **Priority 3,** Start date: ongoing, Completion date: Q4 2026
Comments:	Concept paper (EMA/CVMP/AWP/933451/2022) published in July 2023. This action is included in the EMANS 2028 (objective 4.1.3), carrying forward the reflections in the European Medicines Agencies Network Strategy to 2025 and the EMA's Regulatory Science Strategy.

3.3. New topics/concept papers to be prepared

3.3.1. Revision of the guideline on the summary of product characteristics (SPC) for veterinary medicinal products containing antimicrobial substances

Action:	Development of a concept paper for the revision of the guideline. Revision of the guideline accordingly. **Priority 1,** Start date: Q1 2026, Completion date: beyond 2026
Comments:	Responsible groups: AWP and EWP-V

3.3.2. Concept paper on a revision of the CVMP's reflection paper (public statement) on the use of (fluoro)quinolones in food-producing animals in the European Union: development of resistance and impact on human and animal health

Action:	Development of a concept paper for the revision of the public statement (EMA/CVMP/SAGAM/184651/2005). Development of a reflection paper on the use of (fluoro)quinolones in animals in the European Union. **Priority 2,** Start date: Q1 2026, Completion date: Q4 2026
Comments:	Responsible groups: AWP

4. VICH guidelines and activities

4.1.1. Follow-up activities after the development of a concept paper for revision of VICH GL27

Action:	Follow-up activities after the submission to VICH SC of the concept paper (EMA/CVMP/AWP/585799/2023) for revision of VICH GL27. **Priority 1,** Start date: ongoing, Completion date: beyond 2026
Comments:	Responsible group: AWP.

5. EU regulatory activities

5.1. Dosage review and adjustment of selected veterinary antibiotics (ADRA) project to update dosage recommendations for selected veterinary antibiotics

Action:	Support the CVMP in the implementation of the recommendations of the ADRA tWP.
	Priority 2, Starting date: ongoing, Completion date: beyond 2026
Comments:	This action is included in the EMANS 2028 (objective 4.1.2). Responsible group: ADRA temporary working party.

5.2. Joint inter-agency antimicrobial consumption and resistance analysis (JIACRA) report

Action:	Contribute with expertise to the JIACRA inter-agency drafting group.
	Priority 1, Starting date: ongoing, Completion date: Q4 2026
Comments:	The EMA works closely with the EFSA and the ECDC to analyse the potential relationships between the consumption of antimicrobials by humans and food-producing animals and the occurrence of antimicrobial resistance. The work on the 5th JIACRA report is ongoing.

5.3. Collaboration with EFSA

Action:	Provide contribution to EFSA opinions in accordance with Art. 59 of Regulation (EC) No 726/2004, as amended by Regulation (EU) 2019/5, as required.
Comments:	None.

5.4. Assessor training

Action:	Provide advice / active participation for the training of assessors, as required.
Comments:	None.

6. Activities with external parties

6.1. Meetings with interested parties

Contacts with stakeholders on antimicrobials to exchange information on activities, as required.

6.2. Regulatory authorities outside the EU

Contacts with authorities on antimicrobials to exchange information on activities, as required.

7. Organisational matters

7.1. List of adopted organisational documents

Mandate, objectives, and rules of procedure for working parties under the quality, non-clinical, methodology, clinical and veterinary domains (EMA/299541/2025).

7.2. List of organisational documents to be developed/revised in the forthcoming 2 years

None foreseen.

7.3. List of proposed scientific guidelines for the next work plan[1]

7.3.1. Guidance documents to be finalised after the consultation period

Guideline on the assessment of the risk to public health from antimicrobial resistance due to antimicrobial use in non-food-producing animals.

7.3.2. Guidance documents to be released for consultation

None foreseen.

[1] The actual items to be included in AWP work plan for 2027 will be considered and agreed by the CVMP.